Homology Medicines Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
7
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$42M
Homology Medicines General Information
Description
Developer of genetic medicines intended to address rare diseases using proprietary gene editing and gene therapy technologies into novel treatments. The company operates a proprietary platform designed to utilize human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Contact Information
Website
www.homologymedicines.comCorporate Office
- One Patriots Park
- Bedford, MA 01730
- United States
Corporate Office
- One Patriots Park
- Bedford, MA 01730
- United States
Homology Medicines Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 25-Mar-2024 | $42M | Completed | Generating Revenue | ||
| 6. PIPE | 14-Nov-2020 | Completed | Generating Revenue | |||
| 5. 2PO | 12-Apr-2019 | Completed | Generating Revenue | |||
| 4. IPO | 28-Mar-2018 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 01-Aug-2017 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 02-May-2016 | $43.5M | $43.5M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Homology Medicines Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Homology Medicines Comparisons
Industry
Financing
Details
Homology Medicines Competitors (91)
One of Homology Medicines’s 91 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Rocket Pharmaceuticals | Formerly VC-backed | Cranbury, NJ | ||||
| Neuron23 | Venture Capital-Backed | South San Francisco, CA | ||||
| Eloxx Pharmaceuticals | Formerly VC-backed | Watertown, MA |
Homology Medicines Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Homology Medicines Patents
Homology Medicines Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230399657-A1 | Liver de-targeted recombinant aav capsid proteins | Pending | 17-May-2022 | ||
| US-20230374546-A1 | Bidirectional dual promoter expression vectors and uses thereof | Pending | 11-Mar-2022 | ||
| US-20230323395-A1 | Methods and compositions for the production of adeno-associated virus | Pending | 15-Dec-2021 | ||
| US-20230183659-A1 | Methods and compositions for the purification of adeno-associated virus | Pending | 29-Oct-2021 | ||
| US-20230112648-A1 | Non-naturally occurring polyadenylation elements and methods of use thereof | Pending | 17-Sep-2021 | C12N15/63 |
Homology Medicines Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Homology Medicines Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 4:59 Initiative | Accelerator/Incubator | Minority | ||
| 5AM Ventures | Venture Capital | Minority | ||
| ARCH Venture Partners | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Deerfield Management | Venture Capital | Minority |
Homology Medicines Investments & Acquisitions (2)
Homology Medicines’s most recent deal was a Reverse Merger with Q32 Bio. The deal was made on 25-Mar-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Q32 Bio | 25-Mar-2024 | Reverse Merger | Drug Discovery | ||
| Oxford Biomedica Solutions | 10-Mar-2022 | Joint Venture | Biotechnology |
Homology Medicines ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
22.86 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Biotechnology
Subindustry
of 443
Rank
Percentile
Homology Medicines FAQs
-
When was Homology Medicines founded?
Homology Medicines was founded in 2015.
-
Where is Homology Medicines headquartered?
Homology Medicines is headquartered in Bedford, MA.
-
What is the size of Homology Medicines?
Homology Medicines has 7 total employees.
-
What industry is Homology Medicines in?
Homology Medicines’s primary industry is Biotechnology.
-
Is Homology Medicines a private or public company?
Homology Medicines is a Private company.
-
What is the current valuation of Homology Medicines?
The current valuation of Homology Medicines is .
-
What is Homology Medicines’s current revenue?
The current revenue for Homology Medicines is .
-
How much funding has Homology Medicines raised over time?
Homology Medicines has raised $456M.
-
Who are Homology Medicines’s investors?
4:59 Initiative, 5AM Ventures, ARCH Venture Partners, Alexandria Venture Investments, and Deerfield Management are 5 of 16 investors who have invested in Homology Medicines.
-
Who are Homology Medicines’s competitors?
Regenxbio, Caribou Biosciences, Rocket Pharmaceuticals, Neuron23, and Eloxx Pharmaceuticals are some of the 91 competitors of Homology Medicines.
-
When was Homology Medicines acquired?
Homology Medicines was acquired on 25-Mar-2024.
-
Who acquired Homology Medicines?
Homology Medicines was acquired by Q32 Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
